

Serial No. 09/125,887

Atty Docket No. ~~EX96062~~

c<sup>1</sup> 37. (Amended) A method for generating cytotoxic T cells specific for a tumor antigen, the method comprising contacting a cytotoxic T cell precursor with a population of cells infected with an adenovirus according to claim 20.

38. (Amended) A method for generating cytotoxic T cells specific for a tumor antigen, the method comprising administering to a patient an adenovirus according to claim 20.

41. (New) A composition comprising a cell infected *in vitro* with a replication defective recombinant adenovirus, wherein the adenovirus comprises a sequence encoding an antigenic peptide of a tumor specific protein.

42. (New) The composition of claim 41, wherein the antigenic peptide is encoded by the sequence of one of SEQ ID NO: 1 or 2.

43. (New) The composition of claim 42, wherein the antigenic peptide comprises a fragment from residue 55 to residue 82 of SEQ ID NO: 1.

c<sup>2</sup> 44. (New) The composition of claim 41, wherein the tumor specific protein is selected from a melanoma-specific protein.

45. (New) The composition of claim 41, wherein the tumor specific protein is selected from Mage-1, Mage-3, Bage, Rage, and Gage.

46. (New) A method for preparing a cytotoxic T cell *in vitro*, wherein the T cell is specific for a tumor antigen, the method comprising infecting a cell with a replication defective recombinant adenovirus comprising a sequence encoding an antigenic peptide of a tumor specific protein, and contacting the infected cell with one or more cytotoxic T cell precursor cells, wherein the cell infected with the adenovirus is capable of presenting antigen to the cytotoxic T cell precursor cell.

47. (New) The method of claim 46, wherein the antigenic peptide is encoded by the sequence of one of SEQ ID NO: 1 or 2.

Serial No. 09/125,887  
Atty Docket No.: EX96002

48. (New) The method of claim 47, wherein the antigenic peptide comprises a fragment from residue 55 to residue 82 of SEQ ID NO: 1.

49. (New) The method of claim 46, wherein the tumor specific protein is selected from a melanoma-specific protein.

50. (New) The composition of claim 46, wherein the tumor specific protein is selected from Mage-1, Mage-3, Bage, Rage, and Gage.

---